Biovail suffers from Wellbutrin downturn in third quarter
This article was originally published in Scrip
Executive Summary
Biovailsuffered again in the third quarter after a 69% decrease in Wellbutrin XL sales caused by generic competition resulted in product revenues falling by 4% to $170.5 million.